Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 14/20 | 0.79 |
| ▸ | HHAT | Q5VTY9 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12312732 | 0.92 | CYP2D6 (0.79) | CYP2D6HHATNPC1MITFALDH1A1 | |
| SCHEMBL12312759 | 0.89 | CYP2D6 (0.78) | CYP2D6HHAT | |
| SCHEMBL2795004 | 0.89 | CYP2D6 (1.00) | CYP2D6HHAT | |
| SCHEMBL12312490 | 0.88 | CYP2D6 (0.86) | CYP2D6HHAT | |
| SCHEMBL12312693 | 0.87 | CYP2D6 (0.75) | CYP2D6HHATNPC1MITFALDH1A1 | |
| SCHEMBL13507980 | 0.87 | CYP2D6 (0.75) | CYP2D6HHATNPC1MITFALDH1A1 | |
| SCHEMBL13508040 | 0.87 | CYP2D6 (0.63) | CYP2D6HHAT | |
| SCHEMBL12312758 | 0.83 | CYP2D6 (0.78) | CYP2D6HHAT | |
| SCHEMBL12312968 | 0.83 | CYP2D6 (0.78) | CYP2D6HHAT | |
| SCHEMBL12312969 | 0.83 | CYP2D6 (0.78) | CYP2D6HHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2149560-B1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-13 | — | — | EP | disclosed |
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2149560-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | CACNA1S, CACNA1E, CACNA1B | CYP2D6 834/4885HHAT 2957/4885NPC1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.